ACC: Mavacamten Cuts Need for Surgery in Hypertrophic Cardiomyopathy

MONDAY, April 11, 2022 -- For patients with obstructive hypertrophic cardiomyopathy (HCM), mavacamten improves symptoms and reduces the need for septal reduction therapy (SRT), according to a study presented at the annual meeting of the American...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news